Biotech Values

[dewophile]

Passive immunity is nothing new and several big players are pursuing the same approach. A company like Regeneron has even proven success in the clinic with a similar approach for Ebola. Others are trying to differentiate themselves from everyone else creating antibodies in one way or another for example VIR licensed XNCRs tech to extend half life. What does SRNE bring to the table that others can’t do better?
The CEO overhyping in vitro data (not even pre-clinical animal data) is a red flag.